Affinity Asset Advisors’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

Affinity Asset Advisors’s Portfolio RCKTW Stock Details RCKTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$278	Hold	75,000	–	–	﹤0.01%	113
2026 Q1	$1.18K	Hold	75,000	–	–	﹤0.01%	105
2025 Q4	$1.82K	Hold	75,000	–	–	﹤0.01%	95
2025 Q3	$2.99K	Hold	75,000	–	–	﹤0.01%	96
2025 Q2	$2.16K	Hold	75,000	–	–	﹤0.01%	90
2025 Q1	$3.52K	Hold	75,000	–	–	﹤0.01%	97
2024 Q4	$2.57K	Hold	75,000	–	–	﹤0.01%	85
2024 Q3	$5.25K	Hold	75,000	–	–	﹤0.01%	86
2024 Q2	$4.52K	Hold	75,000	–	–	﹤0.01%	97
2024 Q1	$22.4K	Hold	75,000	–	–	﹤0.01%	95
2023 Q4	$36.8K	Hold	75,000	–	–	0.01%	82
2023 Q3	$7.5K	Hold	75,000	–	–	﹤0.01%	81
2023 Q2	$13.9K	Hold	75,000	–	–	﹤0.01%	70
2023 Q1	$12.3K	Buy	+75,000	New	+$14.5K	﹤0.01%	73

Other funds holding RCKTW

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Affinity Asset Advisors's RCKTW Position: Q2 2026 in Review

Affinity Asset Advisors held its Rocket Pharmaceuticals Warrant (RCKTW) position steady in Q2 2026 at 75,000 shares worth $278. The position accounts for ﹤0.01% of the portfolio, ranked #113.

Affinity Asset Advisors first reported a position in RCKTW in Q1 2023 and has held it in 14 quarters since. The position peaked at $36.8K in Q4 2023. 11 funds tracked by Wall St. Rank hold RCKTW as of Q2 2026.

Affinity Asset Advisors held 75,000 shares of Rocket Pharmaceuticals Warrant worth $278 as of Q2 2026.
Affinity Asset Advisors left its Rocket Pharmaceuticals Warrant share count unchanged in Q2 2026.
Rocket Pharmaceuticals Warrant made up ﹤0.01% of Affinity Asset Advisors's portfolio in Q2 2026, its #113 holding.
Affinity Asset Advisors first reported a position in Rocket Pharmaceuticals Warrant in Q1 2023 and has held it in 14 quarters since.
Affinity Asset Advisors's Rocket Pharmaceuticals Warrant position peaked at $36.8K in Q4 2023.
11 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.